NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-909-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.03 billion
Profitability
Miscellaneous
Employees2,600
OptionableOptionable
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive declared that its Board of Directors has authorized a share repurchase plan on Wednesday, October 25th 2017, which allows the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) issued its earnings results on Tuesday, October, 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.62 by $0.06. The medical device company had revenue of $271.30 million for the quarter, compared to analysts' expectations of $265.70 million. NuVasive had a net margin of 2.24% and a return on equity of 13.87%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
What guidance has NuVasive issued on next quarter's earnings?
NuVasive issued an update on its FY 2019 earnings guidance on Wednesday, February, 20th. The company provided EPS guidance of $2.20-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.47. The company issued revenue guidance of $1.14-1.16 billion, compared to the consensus revenue estimate of $1.17 billion.
What price target have analysts set for NUVA?
18 equities research analysts have issued twelve-month price targets for NuVasive's shares. Their forecasts range from $42.00 to $82.00. On average, they expect NuVasive's share price to reach $64.3529 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. According to Zacks Investment Research, "NuVasive has underperformed its industry over the past three months. The company's third-quarter revenue exceeded the consensus mark. However, earnings fell short of the mark. Operating profit contracted significantly on escalating costs and expenses. Full-year outlook also seems disappointing which fails to indicate any sign of rebound in the near term. Headwinds like pricing pressure, reimbursement issues and competitive landscape are the major downsides. Notably, in the quarter under review, pricing pressure remained stable at a negative 2%, below the industry average. On a positive note, NuVasive delivered balanced growth in both of its business wings. Also, a solid show by the international business buoys optimism. The company expects to see strong demand for new products and positive surgeon conversion efforts. Moreover, contributions from the company’s the recently-completed consolidation of SafePassage was significant." (2/13/2019)
- 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month PT of $50 on shares of NUVA. NUVA has faced a growing number of challenges over the past 18 months, particularly in its US business, which has pressured the stock. We think it is appropriate to remain on the sidelines until we gain more confidence in the reacceleration of US growth and OM improvement. $50 price target is based on a 10x EV/EBITDA multiple on our 2020 EBITDA estimate." (2/11/2019)
- 3. Needham & Company LLC analysts commented, "NUVA’s 3Q18 revenue beat while its EPS missed. Management raised revenue guidance but lowered EPS guidance. Organic growth increased to 8% in 3Q18 from 5% in 2Q18 as improved domestic growth offset slower international growth. Operating margin was 220 bps below consensus as management decided to exploit an improving spine market by reinvesting in SG&A (up 70 bps Y/Y) and R&D (up 50 bps Y/Y). Gross margin met consensus and West Carrollton remains on track to deliver 130-150 bps of margin benefit in 2019. While the margin performance is frustrating, we expect the stronger growth combined with in-sourcing to drive better margin performance in 2019 and reiterate our Buy rating." (10/31/2018)
Has NuVasive been receiving favorable news coverage?
Press coverage about NUVA stock has trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuVasive earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near future.
Are investors shorting NuVasive?
NuVasive saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,930,950 shares, an increase of 35.5% from the January 15th total of 4,378,524 shares. Based on an average daily trading volume, of 612,318 shares, the short-interest ratio is presently 9.7 days. Approximately 11.7% of the company's shares are sold short. View NuVasive's Current Options Chain.
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), ICU Medical (ICUI), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Matthew W. Link, Pres (Age 44)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
- Mr. J. Christopher Barry, Chief Exec. Officer
- Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Eagle Asset Management Inc. (2.57%), Fisher Asset Management LLC (2.47%), Dimensional Fund Advisors LP (2.43%), Anchor Capital Advisors LLC (1.79%), Victory Capital Management Inc. (1.78%) and Macquarie Group Ltd. (1.60%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Lesley H Howe, Matthew Link and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which major investors are selling NuVasive stock?
NUVA stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Victory Capital Management Inc., Eagle Asset Management Inc., Anchor Capital Advisors LLC, American Capital Management Inc., Raymond James & Associates, Dimensional Fund Advisors LP and Tamarack Advisers LP. View Insider Buying and Selling for NuVasive.
Which major investors are buying NuVasive stock?
NUVA stock was bought by a variety of institutional investors in the last quarter, including SG Capital Management LLC, Mesirow Financial Investment Management Equity Management, DNB Asset Management AS, Macquarie Group Ltd., Segall Bryant & Hamill LLC, Hsbc Holdings PLC, Two Sigma Investments LP and Rhumbline Advisers. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $55.42.
How big of a company is NuVasive?
NuVasive has a market capitalization of $2.85 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
What is NuVasive's official website?
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
